Practical Management of Adverse Events and Strategies to Promote Adherence with Targeted Therapies in HR-Positive Breast Cancer

Download these slides from an expert-led symposium on the practical management of adverse events with targeted therapy for HR-positive/HER2-negative breast cancer and strategies to optimize adherence.
Komal Jhaveri, MD
Program Director
Laura M. Spring, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.61 MB
Released: June 6, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Lilly
Novartis Pharmaceuticals Corporation
Sanofi Genzyme

Related Content

Downloadable slideset from Antonio Urbina, MD, on HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Released: September 27, 2022

Antonio Urbina, MD, discusses HIV infection in the transgender population, including strategies for improving patient care and PrEP uptake, from Clinical Care Options (CCO)

Antonio E. Urbina, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 27, 2022 Expired: September 26, 2023

Expert faculty provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings